$EW

Markowitz Wayne sold $13K of EW

Markowitz Wayne (CVP, JAPAC) sold 146 shares of Edwards Lifesciences Corp (EW) at $86.03 on 2026-07-30.

Original reporting
SEC EDGAR · Markowitz Wayne
Published Jul 30, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EW
Neutral
high confidence
Mentioned
$EW
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EWNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings). It does not include any company performance, guidance, or regulatory development.

02

Market read

Traders may note insider selling, but the disclosed dollar amount is small and lacks accompanying fundamental catalysts.

03

What to watch

The absence of a stated 10b5-1 plan does not by itself imply negative information; insider sales can still be discretionary and non-informational at small sizes.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-30, after-hours SEC Form 4 disclosure

Background

This is an SEC Form 4 insider transaction disclosure for Edwards Lifesciences (EW).

Company-level read

Ticker impact

$EWNeutralHigh confidence
Context

Edwards Lifesciences insider Markowitz Wayne sold 146 shares on 2026-07-30 at $86.0338, totaling about $12.6K.

Expected impact

Low likelihood of a sustained price move; any impact would be limited to short-term sentiment.

Evidence & confidence

The filing is a primary-source insider transaction, but the transaction value (~$12.6K) is modest relative to typical market-moving thresholds and provides no new operating or guidance information.

Market effects

No clear sector read-through from a small, routine insider sale.

None indicated.

None indicated.

Counterpoint

The sale may be unrelated to outlook (taxes, diversification, or pre-planned liquidity needs), especially since the filing does not provide a bearish thesis.

Key entities

  • Edwards Lifesciences Corp

    US-listed company subject of the Form 4 insider sale disclosure.

  • Markowitz Wayne

    Officer who reported the open-market sale of EW shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EWMedAI 8/10

CMS Expands Medicare Coverage for Edwards TAVR

CMS expanded Medicare coverage for Edwards Lifesciences' TAVR procedure to asymptomatic severe aortic stenosis patients. The company reiterated its 10-11% sales growth guidance. Shares (EW) fell 2.7% to $84.37. Analysts see upside, with Jefferies raising its price target to $105.

$EWMedAI 8/10

BD Taps Edwards Lifesciences Veteran Gary Sorsher to Lead Global Quality

BD appointed Gary Sorsher, former Chief Quality Officer at Edwards Lifesciences, as its new Executive Vice President and Chief Quality Officer. Sorsher brings over 30 years of experience in quality roles. The move follows Jeffrey Silvestri's planned retirement. BD's CEO highlighted Sorsher's global experience and focus on continuous improvement. Edwards Lifesciences received FDA clearance for its Ecliptis left atrial appendage exclusion system, entering the surgical stroke-prevention market. BD

$EWMed

Edwards Lifesciences, Medtronic score CMS win over TAVR

Edwards Lifesciences (EW) and Medtronic (MDT) welcomed CMS's decision to expand Medicare coverage for TAVR to asymptomatic severe aortic stenosis patients, citing improved access and streamlined care. EW shares fell 2% to $84.31, MDT dropped 1% to $90.70. CMS's decision was based on EW's Early TAVR trial data, showing lower adverse outcomes for prompt TAVR. Analysts view the decision as positive for TAVR growth.

$EWHigh

CMS TAVR changes, a boon for Edwards

The CMS has expanded Medicare coverage for TAVR procedures to include asymptomatic severe aortic stenosis patients. Edwards Lifesciences Corp. has advocated for this change, which may benefit the company.

$EWHighAI 8/10

Edwards Lifesciences stock price target maintained at $85 by Canaccord

Canaccord maintained a Hold rating and $85 price target for Edwards Lifesciences (EW) after a Medicare coverage decision on TAVR procedures. The stock trades at $86.77, above the target but below consensus. CMS finalized changes Edwards requested, expanding coverage for asymptomatic severe aortic stenosis. Edwards confirmed its 2026 financial guidance, expecting long-term benefits. Analysts have mixed price targets, ranging from $84 to $110. The company reported strong Q2 results, with sales of

$EWHighAI 8/10

Stifel sees CMS TAVR coverage update as positive for Edwards

CMS finalized TAVR coverage, benefiting Edwards Lifesciences due to its market leadership. Stifel analysts view the update positively, supporting Edwards' revenue growth outlook. TAVR represents 75% of Edwards' revenues and 5.5% of Medtronic's. CMS also initiated coverage analysis for devices treating aortic regurgitation, including Edwards' J-Valve.